Although high-density lipoprotein cholesterol has been deemed the “good cholesterol,” this label may be misleading and outdated given that there is little evidence to support a causal relationship with CVD risk reduction.
Barriers to pharmacotherapy for osteoporosis warrant further investigation in order to reduce the elevated mortality and morbidity rates associated with the disease.
To learn more about weight-neutral diabetes care, Endocrinology Advisor checked in with experts in the field to discuss existing research and takeaways for clinicians.
Can a weight-neutral approach improve care for patients with diabetes?
